Lung Trials

Pfizer C3651009

A phase 1b, 12-week, open-label study to assess the safety, Tolerability, pharmacokinetics and pharmacodynamics Following repeated subcutaneous administrations of PF-06946860 in patients with non small cell lung cancer and Cachexia

Mirati  516-005

A Randomized Phase 3 Study of Sitravatinib in Combination with Nivolumab Versus Docetaxel in Patients with Advanced Non-Squamous Non-Small Cell Lung Cancer with Disease Progression On or After Platinum-Based Chemotherapy in Combination with Checkpoint Inhibitor Therapy

Merck MK7339-012

Phase 3 Study of Pembrolizumab with Concurrent Chemoradiation Therapy Followed by Pembrolizumab with or without Olaparib in Stage III NSCLC
Awaiting Activation

Merck MK7339-013

A Phase 3 Study of Pembrolizumab (MK-3475) in Combination with Concurrent Chemoradiation Therapy Followed by Pembrolizumab with or without Olaparib, Compared to Concurrent Chemoradiation Therapy Followed by Placebo in Participants with Newly Diagnosed Treatment-Naïve Limited-Stage Small Cell Lung Cancer (LS-SCLC)

Genentech BO42592

A Phase II, Randomized, Double-Blind, Placebo-Controlled Study Of Tiragolumab In Combination With Atezolizumab Plus Pemetrexed And Carboplatin/Cisplatin Versus Pembrolizumab Plus Pemetrexed And Carboplatin/Cisplatin In Patients With Previously Untreated Advanced non-Squamous Non-Small Cell Lung Cancer

Fort Wayne North Office
(260) 484-8830
2514 E Dupont Road, Suite 100
Fort Wayne, IN 46825

Fort Wayne South Office
(260) 436-0800
7910 West Jefferson Boulevard, Suite 108
Fort Wayne, Indiana 46804

©2019 Fort Wayne Medical Oncology and Hematology. All Rights Reserved.